{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:40:31Z","timestamp":1771566031781,"version":"3.50.1"},"reference-count":35,"publisher":"CMA Impact Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["cmajo"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.9778\/cmajo.20200319","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:13:56Z","timestamp":1644945236000},"page":"E109-E118","source":"Crossref","is-referenced-by-count":6,"title":["Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study"],"prefix":"10.9778","volume":"10","author":[{"given":"Anat","family":"Fisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin R.","family":"Dormuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"382","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"2022021508001520000_10.1.E109.1","unstructured":"(2019) Prescribed drug spending in Canada, 2019: a focus on public drug programs (Canadian Institute for Health Information, Ottawa) Available: www.cihi.ca\/en\/prescribed-drug-spending-in-canada-2019 . accessed 2020 Dec. 1."},{"key":"2022021508001520000_10.1.E109.2","unstructured":"Kobelt G Kasteng F (2009) Access to innovative treatments in rheumatoid arthritis in Europe: a report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA) (Lund University, European Federation of Pharmaceutical Industry Associations, Sweden) Available: http:\/\/www.comparatorreports.se\/Access%20to%20RA%20Treatments%20October%202009.pdf . accessed 2020 Dec. 1."},{"key":"2022021508001520000_10.1.E109.3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.41138","article-title":"Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid","volume":"72","author":"McCormick","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022021508001520000_10.1.E109.4","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2015.0402.018"},{"key":"2022021508001520000_10.1.E109.5","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"key":"2022021508001520000_10.1.E109.6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1186\/s12913-019-4680-2","article-title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","volume":"19","author":"Mansell","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"2022021508001520000_10.1.E109.7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/1756-185X.13305","article-title":"Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"21","author":"Bae","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 10","key":"2022021508001520000_10.1.E109.8","first-page":"911","article-title":"Efficacy and safety of biological therapy and target synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"68","author":"Sepriano","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022021508001520000_10.1.E109.9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2017.02.003","article-title":"Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases: a systematic review and meta-analysis","volume":"79","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"key":"2022021508001520000_10.1.E109.10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.55563\/clinexprheumatol\/pa6lap","article-title":"Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons","volume":"39","author":"Convertino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2022021508001520000_10.1.E109.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"2022021508001520000_10.1.E109.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000710"},{"key":"2022021508001520000_10.1.E109.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"2022021508001520000_10.1.E109.14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001016"},{"key":"2022021508001520000_10.1.E109.15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apt.14997","article-title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","volume":"49","author":"Feagan","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022021508001520000_10.1.E109.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0881-y"},{"key":"2022021508001520000_10.1.E109.17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2018.77975","article-title":"Biosimilar switching \u2014 current state of knowledge","volume":"56","author":"Wiland","year":"2018","journal-title":"Reumatologia"},{"key":"2022021508001520000_10.1.E109.18","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.3390\/ijerph17165800","article-title":"Clinical and regulatory concerns of biosimilars: a review of literature","volume":"17","author":"Halimi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2022021508001520000_10.1.E109.19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jcag\/gwz043","article-title":"The law and ethics of switching from biologic to biosimilar in Canada","volume":"3","author":"Murdoch","year":"2020","journal-title":"J Can Assoc Gastroenterol"},{"key":"2022021508001520000_10.1.E109.20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","article-title":"Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies","volume":"35","author":"Numan","year":"2018","journal-title":"Adv Ther"},{"key":"2022021508001520000_10.1.E109.21","unstructured":"Biosimilars Initiative for patients: current switch period (British Columbia Ministry of Health, Victoria) Available: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/pharmacare-for-bc-residents\/what-we-cover\/biosimilars-initiative-patients . accessed 2022 Jan. 10."},{"key":"2022021508001520000_10.1.E109.22","unstructured":"How to submit a special authority request (British Columbia Ministry of Health, Victoria) Available: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/prescribers\/special-authority\/submitting-a-special-authority-request-information-for-prescribers . accessed 2020 Dec. 1."},{"key":"2022021508001520000_10.1.E109.23","unstructured":"Biosimilars Initiative: infliximab (British Columbia Ministry of Health, Victoria) Available: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/health-drug-coverage\/pharmacare\/patient-info-infliximab_final.pdf . accessed 2022 Jan. 10."},{"key":"2022021508001520000_10.1.E109.24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/pds.4957","article-title":"A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia","volume":"29","author":"Dormuth","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022021508001520000_10.1.E109.25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/pds.5008","article-title":"Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia \u2014 an interim report","volume":"29","author":"Fisher","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022021508001520000_10.1.E109.26","unstructured":"(Mar. 18, 2020) Province declares state of emergency to support COVID-19 response [news release] (BC Gov News\/BC Public Safety and Solicitor General, Victoria) Available: https:\/\/news.gov.bc.ca\/releases\/2020PSSG0017-000511 . accessed 2020 Dec. 1."},{"key":"2022021508001520000_10.1.E109.27","unstructured":"(Dec. 9, 2021) Impact of COVID-19 on Canada\u2019s health care systems [homepage on Internet] (Canadian Institute for Health Information, Ottawa) Available: https:\/\/www.cihi.ca\/en\/covid-19-resources\/impact-of-covid-19-on-canadas-health-care-systems . accessed 2022 Jan. 1."},{"key":"2022021508001520000_10.1.E109.28","doi-asserted-by":"crossref","first-page":"813405","DOI":"10.3389\/fphar.2021.813405","article-title":"Household drug stockpiling and panic buying of drugs during the COVID-19 pandemic: a study from Jordan","volume":"12","author":"Al Zoubi","year":"2021","journal-title":"Front Pharmacol"},{"key":"2022021508001520000_10.1.E109.29","doi-asserted-by":"crossref","first-page":"e0253944","DOI":"10.1371\/journal.pone.0253944","article-title":"Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic","volume":"16","author":"Karlsson","year":"2021","journal-title":"PloS One"},{"key":"2022021508001520000_10.1.E109.30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1715163520929387","article-title":"Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic","volume":"153","author":"Elbeddini","year":"2020","journal-title":"Can Pharm J"},{"key":"2022021508001520000_10.1.E109.31","first-page":"e129","article-title":"Income-based drug coverage in British Columbia: the impact on private and public expenditures","volume":"2","author":"Morgan","year":"2006","journal-title":"Healthc Policy"},{"issue":"Suppl 2","key":"2022021508001520000_10.1.E109.32","first-page":"1712","article-title":"AB1231 efficacy and cost analysis of a systematic switch from originator infliximab to biossimilar CT-Pp13 of all patients with inflammatory arthritis from a single centre","volume":"77","author":"Valido","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022021508001520000_10.1.E109.33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-12-199906150-00019"},{"key":"2022021508001520000_10.1.E109.34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: Does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"Suppl 2","key":"2022021508001520000_10.1.E109.35","first-page":"835","article-title":"Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or CT-p13 in the Turkish population","volume":"76","author":"Phillips","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["CMAJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.9778\/cmajo.20200319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:30:04Z","timestamp":1674779404000},"score":1,"resource":{"primary":{"URL":"http:\/\/cmajopen.ca\/lookup\/doi\/10.9778\/cmajo.20200319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.9778\/cmajo.20200319"],"URL":"https:\/\/doi.org\/10.9778\/cmajo.20200319","relation":{},"ISSN":["2291-0026"],"issn-type":[{"value":"2291-0026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}